glyburide has been researched along with Developmental Disabilities in 8 studies
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide
glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.
Developmental Disabilities: Disorders in which there is a delay in development based on that expected for a given age level or stage of development. These impairments or disabilities originate before age 18, may be expected to continue indefinitely, and constitute a substantial impairment. Biological and nonbiological factors are involved in these disorders. (From American Psychiatric Glossary, 6th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ioacara, S | 1 |
| Flanagan, S | 1 |
| Fröhlich-Reiterer, E | 1 |
| Goland, R | 1 |
| Fica, S | 1 |
| Della Manna, T | 1 |
| Battistim, C | 1 |
| Radonsky, V | 1 |
| Savoldelli, RD | 1 |
| Damiani, D | 1 |
| Kok, F | 1 |
| Pearson, ER | 1 |
| Ellard, S | 2 |
| Hattersley, AT | 4 |
| Reis, AF | 1 |
| Mohamadi, A | 1 |
| Clark, LM | 1 |
| Lipkin, PH | 1 |
| Mahone, EM | 1 |
| Wodka, EL | 1 |
| Plotnick, LP | 1 |
| Jones, AG | 1 |
| Sang, Y | 1 |
| Ni, G | 1 |
| Gu, Y | 1 |
| Liu, M | 1 |
| Slingerland, AS | 1 |
| Nuboer, R | 1 |
| Hadders-Algra, M | 1 |
| Bruining, GJ | 1 |
| Shimomura, K | 1 |
| Hörster, F | 1 |
| de Wet, H | 1 |
| Flanagan, SE | 1 |
| Wolf, NI | 1 |
| Ashcroft, F | 1 |
| Ebinger, F | 1 |
| Mlynarski, W | 1 |
| Tarasov, AI | 1 |
| Gach, A | 1 |
| Girard, CA | 1 |
| Pietrzak, I | 1 |
| Zubcevic, L | 1 |
| Kusmierek, J | 1 |
| Klupa, T | 1 |
| Malecki, MT | 1 |
| Ashcroft, FM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Timing of Initiation of Sulphonylurea Therapy on Neurodevelopmental Outcomes in Individuals With Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome Due to the V59M Mutation in the KCNJ11 Gene[NCT05751525] | 21 participants (Anticipated) | Observational | 2016-07-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 other studies available for glyburide and Developmental Disabilities
| Article | Year |
|---|---|
First case of neonatal diabetes with KCNJ11 Q52R mutation successfully switched from insulin to sulphonylurea treatment.
Topics: Developmental Disabilities; Diabetes Mellitus; Epilepsy; Glyburide; Humans; Hypoglycemic Agents; Inf | 2017 |
Glibenclamide unresponsiveness in a Brazilian child with permanent neonatal diabetes mellitus and DEND syndrome due to a C166Y mutation in KCNJ11 (Kir6.2) gene.
Topics: Brazil; Child, Preschool; Developmental Disabilities; Diabetes Mellitus; Epilepsy; Female; Glyburide | 2008 |
Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15-yr-old boy with neonatal diabetes mellitus and intermediate DEND syndrome: extending the age of KCNJ11 mutation testing in neonatal DM.
Topics: Administration, Oral; Adolescent; Continuity of Patient Care; Developmental Disabilities; Diabetes M | 2010 |
Reevaluation of a case of type 1 diabetes mellitus diagnosed before 6 months of age.
Topics: Administration, Oral; Adolescent; Amino Acid Substitution; Developmental Disabilities; Diabetes Mell | 2010 |
AV59M KCNJ11 gene mutation leading to intermediate DEND syndrome in a Chinese child.
Topics: Asian People; Developmental Disabilities; Diabetes Mellitus, Type 1; Glyburide; Humans; Hypoglycemic | 2011 |
Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the
Topics: Amino Acid Substitution; Blood Glucose; Developmental Disabilities; Diabetes Mellitus; Epilepsy; Fol | 2006 |
A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain.
Topics: Animals; Anticonvulsants; Cell Membrane; Child, Preschool; Developmental Disabilities; Diabetes Mell | 2007 |
Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11.
Topics: Child; Child, Preschool; Developmental Disabilities; Diabetes Mellitus; DNA Mutational Analysis; Fem | 2007 |